Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2005

Open Access 01-12-2005 | Review

The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded

Authors: Melvin R Hayden, James R Sowers, Suresh C Tyagi

Published in: Cardiovascular Diabetology | Issue 1/2005

Login to get access

Abstract

The vascular endothelial basement membrane and extra cellular matrix is a compilation of different macromolecules organized by physical entanglements, opposing ionic charges, chemical covalent bonding, and cross-linking into a biomechanically active polymer. These matrices provide a gel-like form and scaffolding structure with regional tensile strength provided by collagens, elasticity by elastins, adhesiveness by structural glycoproteins, compressibility by proteoglycans – hyaluronans, and communicability by a family of integrins, which exchanges information between cells and between cells and the extracellular matrix of vascular tissues.
Each component of the extracellular matrix and specifically the capillary basement membrane possesses unique structural properties and interactions with one another, which determine the separate and combined roles in the multiple diabetic complications or diabetic opathies.
Metabolic syndrome, prediabetes, type 2 diabetes mellitus, and their parallel companion (atheroscleropathy) are associated with multiple metabolic toxicities and chronic injurious stimuli. The adaptable quality of a matrix or form genetically preloaded with the necessary information to communicate and respond to an ever-changing environment, which supports the interstitium, capillary and arterial vessel wall is individually examined.
Appendix
Available only for authorised users
Literature
1.
Siperstein MD, Unger RH, Madison LL: Studies of muscle capillary basement membranes in normal subjects, diabetic, and prediabetic patients. J Clin Invest. 1968, 47 (9): 1973-1999.PubMedCentralCrossRefPubMed
2.
Siperstein MD, Unger RH, Madison LL: Further electron microscopic studies of diabetic microangiopathy. Adv Metab Disord. 1970, 1: 261.PubMed
3.
Merimee TJ, Siperstein MD, Fineberg SE, McKusick VA: The microangiopathic lesions of diabetes mellitus: an evaluation of possible causative factors. Trans Assoc Am Physicians. 1970, 83: 102-112.PubMed
4.
Merimee TJ, Siperstein MD, Hall JD, Fineberg SE: Capillary basement membrane structure: a comparative study of diabetics and sexual ateliotic dwarfs. J Clin Invest. 1970, 49 (12): 2161-2164.PubMedCentralCrossRefPubMed
5.
Siperstein MD: Capillary basement membranes and diabetic microangiopathy. Adv Intern Med. 1972, 18: 325-344.PubMed
6.
Feingold KR, Browner WS, Siperstein MD: Prospective studies of muscle capillary basement membrane width in prediabetics. J Clin Endocrinol Metab. 1989, 69 (4): 784-789.CrossRefPubMed
7.
Siperstein MD: Diabetic microangiopathy, genetics, environment, and treatment. Am J Med. 1988, 85 (5A): 119-130. 10.1016/0002-9343(88)90404-4.CrossRefPubMed
8.
Klein RF, Feingold KR, Morgan C, Stern WH, Siperstein MD: Relationship of muscle capillary basement membrane thickness and diabetic retinopathy. Diabetes Care. 1987, 10 (2): 195-199.CrossRefPubMed
9.
Feingold KR, Lee TH, Chung MY, Siperstein MD: Muscle capillary basement membrane width in patients with vacor-induced diabetes mellitus. J Clin Invest. 1986, 78 (1): 102-107.PubMedCentralCrossRefPubMed
10.
Siperstein MD: Diabetic microangiopathy and the control of blood glucose. N Engl J Med. 1983, 309 (25): 1577-1599.CrossRefPubMed
11.
Kilo C, Vogler N, Williamson JR: Muscle capillary basement membrane changes related to aging and to diabetes mellitus. Diabetes. 1972, 21 (8): 881-905.CrossRefPubMed
12.
Williamson JR, Vogler NJ, Kilo C: Early capillary basement membrane changes in subjects with diabetes mellitus. Adv Metab Disord. 1973, 2: 363-371.PubMed
13.
Fajans SS, Williamson JR, Weissman PN, Bogler NJ, Kilo C, Conn JW: Basement membrane thickening in latent diabetes. Adv Metab Disord. 1973, 2: 393-399.PubMed
14.
Koenig RJ, Peterson CM, Kilo C, Cerami A, Williamson JR: Hemoglobin AIc as an indicator of the degree of glucose intolerance in diabetes. Diabetes. 1976, 25 (3): 230-232.CrossRefPubMed
15.
Williamson JR, Rowold E, Hoffman P, Kilo C: Influence of fixation and morphometric technics on capillary basement-membrane thickening prevalence data in diabetes. Diabetes. 1976, 25 (7): 604-613.CrossRefPubMed
16.
Williamson JR, Kilo C: Current status of capillary basement-membrane disease in diabetes mellitus. Diabetes. 1977, 26 (1): 65-73.CrossRefPubMed
17.
Ganda OP, Soeldner JS, Gleason RE, Smith TM, Kilo C, Williamson JR: Monozygotic triplets with discordance for diabetes mellitus and diabetic microangiopathy. Diabetes. 1977, 26 (5): 469-479.CrossRefPubMed
18.
Kilo C, Williamson JR: Basement membranes in muscle capillaries. Adv Exp Med Biol. 1979, 124: 133-139.CrossRefPubMed
19.
Olson ND, Nuttall FQ, Sinha A, Kilo C, Williamson JR: Thin muscle capillary basement membranes in myotonic dystrophy. Diabetes. 1979, 28 (7): 686-689.CrossRefPubMed
20.
Chang K, Uitto J, Rowold EA, Grant GA, Kilo C, Williamson JR: Increased collagen cross-linkages in experimental diabetes: reversal by beta- aminopropionitrile and D-penicillamine. Diabetes. 1980, 29 (10): 778-781.CrossRefPubMed
21.
Tilton RG, Hoffmann PL, Kilo C, Williamson JR: Pericyte degeneration and basement membrane thickening in skeletal muscle capillaries of human diabetics. Diabetes. 1981, 30 (4): 326-334.CrossRefPubMed
22.
Uitto J, Perejda AJ, Grant GA, Rowold EA, Kilo C, Williamson JR: Glycosylation of human glomerular basement membrane collagen: increased content of hexose in ketoamine linkage and unaltered hydroxylysine-O-glycosides in patients with diabetes. Connect Tissue Res. 1982, 10 (3–4): 287-296.CrossRefPubMed
23.
Williamson JR, Kilo C: Capillary basement membranes in diabetes. Diabetes. 1983, 32 (Suppl 2): 96-100.CrossRefPubMed
24.
Ganda OP, Williamson JR, Soeldner JS, Gleason RE, Kilo C, Kaldany A, Miller JP, Garovoy MR, Carpenter CB: Muscle capillary basement membranewidth and its relationship to diabetes mellitus in monozygotic twins. Diabetes. 1983, 32 (6): 549-556.CrossRefPubMed
25.
Barnett AH, Spiliopoulos AJ, Pyke DA, Stubbs WA, Rowold E, Hoffmann P, Faller A, Kilo C, Miller JP, Williamson JR: Muscle capillary basement membrane in identical twins discordant for insulin-dependent diabetes. Diabetes. 1983, 32 (6): 557-560.CrossRefPubMed
26.
Tilton RG, Faller AM, Burkhardt JK, Hoffmann PL, Kilo C, Williamson JR: Pericyte degeneration and acellular capillaries are increased in the feet of human diabetic patients. Diabetologia. 1985, 28 (12): 895-900. 10.1007/BF00703132.CrossRefPubMed
27.
Tilton RG, LaRose LS, Kilo C, Williamson JR: Absence of degenerative changes in retinal and uveal capillary pericytes in diabetic rats. Invest Ophthalmol Vis Sci. 1986, 27 (5): 716-721.PubMed
28.
Rogers DG, White NH, Santiago JV, Miller JP, Weldon VV, Kilo C, Williamson JR: Glycemic control and bone age are independently associated with muscle capillary basement membrane width in diabetic children after puberty. Diabetes Care. 1986, 9 (5): 453-459.CrossRefPubMed
29.
Williamson JR, Tilton RG, Chang K, Kilo C: Basement membraneabnormalities in diabetes mellitus: relationship to clinical microangiopathy. Diabetes Metab Rev. 1988, 4 (4): 339-370.CrossRefPubMed
30.
Tsilibary EC: Microvascular basement membranes in diabetes mellitus. J Pathol. 2003, 200 (4): 537-54. 10.1002/path.1439.CrossRefPubMed
31.
Hollertz O: Sulphur: the vulnerable factor X in atherosclerosis. Med Hypotheses. 2002, 59 (1): 35-38. 10.1016/S0306-9877(02)00193-7.CrossRefPubMed
32.
Yurchenco PD, Schittny JC: Molecular architecture of basement membranes. FASEB J. 1990, 4 (6): 1577-1590.PubMed
33.
Weber S, Dolz R, Timpl R, Fessler JH, Engel J: Reductive cleavage and reformation of the interchain and intrachain disulfide bonds in the globular hexameric domain NC1 involved in network assembly of basement membrane collagen (type IV). Eur J Biochem. 1988, 175 (2): 229-233. 10.1111/j.1432-1033.1988.tb14188.x.CrossRefPubMed
34.
Timpl R: Structure and biological activity of basement membrane proteins. Eur J Biochem. 1989, 180 (3): 487-502. 10.1111/j.1432-1033.1989.tb14673.x.CrossRefPubMed
35.
Sherratt MJ, Baldock C, Haston JL, Holmes DF, Jones CJ, Shuttleworth CA, Wess TJ, Kielty CM: Fibrillin microfibrils are stiff reinforcing fibres in compliant tissues. J Mol Biol. 2003, 332 (1): 183-193. 10.1016/S0022-2836(03)00829-5.CrossRefPubMed
36.
Sterzel RB, Hartner A, Schlotzer-Schrehardt U, Voit S, Hausknecht B, Doliana R, Colombatti A, Gibson MA, Braghetta P, Bressan GM: Elastic fiber proteins in the glomerular mesangium in vivo and in cell culture. Kidney Int. 2000, 58 (4): 1588-1602. 10.1046/j.1523-1755.2000.00320.x.CrossRefPubMed
37.
Conde-Knape K: Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev. 2001, 17 (6): 412-421. 10.1002/dmrr.236.CrossRefPubMed
38.
Pillarisetti S: Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med. 2000, 10 (2): 60-65. 10.1016/S1050-1738(00)00048-7.CrossRefPubMed
39.
Olsson U, Bondjers G, Camejo G: Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Diabetes. 1999, 48 (3): 616-622.CrossRefPubMed
40.
Florian JA, Kosky JR, Ainslie K, Pang Z, Dull RO, Tarbell JM: Heparan sulfate proteoglycan is a mechanosensor on endothelial cells. Circ Res. 2003, 93 (10): e136-e142. 10.1161/01.RES.0000101744.47866.D5.CrossRefPubMed
41.
Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose EJ: Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol. 1992, 8: 365-393. 10.1146/annurev.cb.08.110192.002053.CrossRefPubMed
42.
43.
Yurchenco PD, Schittny JC: Molecular architecture of basement membranes. FASEB J. 1990, 4 (6): 1577-1590.PubMed
44.
Timpl R: Structure and biological activity of basement membrane proteins. Eur J Biochem. 1989, 180 (3): 487-502. 10.1111/j.1432-1033.1989.tb14673.x.CrossRefPubMed
45.
Lebel SP, Chen Y, Gingras D, Chung AE, Bendayan M: Morphofunctional studies of the glomerular wall in mice lacking entactin-1. J Histochem Cytochem. 2003, 51 (11): 1467-1478.PubMedCentralCrossRefPubMed
46.
Danen EH, Sonnenberg A: Erratum: Integrins in regulation of tissue development and function. J Pathol. 2003, 201 (4): 632-641. 10.1002/path.1472. J Pathol; 200: 471–480CrossRefPubMed
47.
Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell. 2002, 110 (6): 673-687. 10.1016/S0092-8674(02)00971-6.CrossRefPubMed
48.
van der Flier A, Sonnenberg A: Function and interactions of integrins. Cell Tissue Res. 2001, 305 (3): 285-298. 10.1007/s004410100417.CrossRefPubMed
49.
Goldsmith EC, Borg TK: The dynamic interaction of the extracellular matrix in cardiac remodeling. J Card Fail. 2002, 8 (6 Suppl): S314-S318. 10.1054/jcaf.2002.129258.CrossRefPubMed
50.
Arnaout MA: Integrin structure: new twists and turns in dynamic cell adhesion. Immunol Rev. 2002, 186: 125-140. 10.1034/j.1600-065X.2002.18612.x.CrossRefPubMed
51.
Tanaka Y: [Adhesion molecules: relevance to basic and clinical research]. J UOEH. 2001, 23 (4): 421-429.PubMed
52.
Brown E, Hogg N: Where the outside meets the inside: integrins as activators and targets of signal transduction cascades. Immunol Lett. 1996, 54 (2–3): 189-193. 10.1016/S0165-2478(96)02671-5.CrossRefPubMed
53.
Halvorson MJ, Coligan JE, Sturmhofel K: The vitronectin receptor (alpha V beta 3) as an example for the role of integrins in T lymphocyte stimulation. Immunol Res. 1996, 15 (1): 16-29.CrossRefPubMed
54.
Faull RJ, Ginsberg MH: Inside-out signaling through integrins. J Am Soc Nephrol. 1996, 7 (8): 1091-1097.PubMed
55.
Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S: Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev. 2003, 22 (2–3): 153-166. 10.1023/A:1023091214123.CrossRefPubMed
56.
Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, Tsao PS: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res. 2001, 88 (12): 1291-1298.CrossRefPubMed
57.
Camp TM, Tyagi SC, Senior RM, Hayden MR, Tyagi SC: Gelatinase B(MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia. 2003, 46 (10): 1438-1445. 10.1007/s00125-003-1200-y.CrossRefPubMed
58.
Hayden MR, Tyagi SC: Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol. 2002, 1 (1): 3-10.1186/1475-2840-1-3.PubMedCentralCrossRefPubMed
59.
Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes. 1999, 48: 491-498.CrossRefPubMed
60.
Death AK, Fisher EJ, McGrath KC, Yue DK: High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis. 2003, 168 (2): 263-269. 10.1016/S0021-9150(03)00140-0.CrossRefPubMed
61.
Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Dano K: Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest. 1997, 77 (4): 345-355.PubMed
62.
Arihiro S, Ohtani H, Hiwatashi N, Torii A, Sorsa T, Nagura H: Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology. 2001, 39 (1): 50-59. 10.1046/j.1365-2559.2001.01142.x.CrossRefPubMed
63.
von Luttichau I, Djafarzadeh R, Henger A, Cohen CD, Mojaat A, Jochum M, Ries C, Nelson PJ, Kretzler M: Identification of a signal transduction pathway that regulates MMP-9 mRNA expression in glomerular injury. Biol Chem. 2002, 383 (7–8): 1271-1275. 10.1515/BC.2002.142.PubMed
64.
Asanuma K, Shirato I, Ishidoh K, Kominami E, Tomino Y: Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int. 2002, 62 (3): 822-831. 10.1046/j.1523-1755.2002.00539.x.CrossRefPubMed
65.
Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H: Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000, 15 (9): 1379-1383. 10.1093/ndt/15.9.1379.CrossRefPubMed
66.
Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991, 87 (2): 432-438.PubMedCentralCrossRefPubMed
67.
Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991, 87 (2): 432-438.PubMedCentralCrossRefPubMed
68.
Clancy RM, Leszczynska-Piziak J, Abramson SB: Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest. 1992, 90 (3): 1116-1121.PubMedCentralCrossRefPubMed
69.
Mudaliar SR, Henry RR: Management and prevention of diabetic complications. Atlas of Clinical Endocrinology. Series Editor: Korenman SG. Diabetes Editor: Kahn Ronald C. 2000, Blackwell Science Inc. Developed by Current Medicine, Inc., Philadelphia, 2: 81-94.
70.
Harris MI: Summary. Diabetes in America, NIH Publication No. 95-1468. Edited by: Harris MI, Cowie CC, Stern MP. 1995, Washington D.C: US Government Printing Office, 1-14.
71.
Fagan TC, Deedwania PC: The cardiovascular dysmetabolic syndrome. Am J Med. 1998, 105 (1A): 77S-82S. 10.1016/S0002-9343(98)00216-2.CrossRefPubMed
72.
Garber AJ: Vascular disease and lipids in diabetes. Med Clin North Am. 1998, 82: 931-948. 10.1016/S0025-7125(05)70030-4.CrossRefPubMed
73.
Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol. 2003, 2 (1): 2-10.1186/1475-2840-2-2.PubMedCentralCrossRefPubMed
74.
Sowers JR: Insulin resistance and hypertension. Am J Physiiol Heart Circ Physiol. 2004, 286 (5): H1597-H1562. 10.1152/ajpheart.00026.2004.CrossRef
75.
Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001, 12 (6): 1211-1217.PubMed
76.
Hayden MR, Tyagi SC: Myocardial redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and congestive heart failure. Med Sci Monit. 2003, 9 (7): SR35-SR52.PubMed
77.
Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002, 359 (9324): 2140-2144. 10.1016/S0140-6736(02)09089-X.CrossRefPubMed
78.
National Diabetes Data Group: Diabetes in America. 1995, Bethesda, Maryland, USA, 1-730. NIH Publication no. 95-1468, 2
79.
Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A. 1992, 89 (22): 11059-11063.PubMedCentralCrossRefPubMed
80.
Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL: Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 1997, 100 (1): 115-126.PubMedCentralCrossRefPubMed
81.
Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000, 404 (6779): 787-790. 10.1038/35008121.CrossRefPubMed
82.
Metadata
Title
The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded
Authors
Melvin R Hayden
James R Sowers
Suresh C Tyagi
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2005
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-4-9

Other articles of this Issue 1/2005

Cardiovascular Diabetology 1/2005 Go to the issue

Original investigation

Prevalence of antiplatelet therapy in patients with diabetes

Review

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

Original investigation

Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study

Original investigation

Endothelial cell injury by high glucose and heparanase is prevented by insulin, heparin and basic fibroblast growth factor

Methodology

Hypertension control: results from the Diabetes Care Program of Nova Scotia registry and impact of changing clinical practice guidelines

Original investigation

Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits